Annual report pursuant to Section 13 and 15(d)

License Agreement

v3.20.1
License Agreement
12 Months Ended
Dec. 31, 2019
License Agreement [Abstract]  
License Agreement

10. License Agreement

In June 2015, the Company entered into an exclusive license agreement with Onyx Therapeutics, Inc. (“Onyx”), a wholly owned subsidiary of Amgen, Inc., for a worldwide, exclusive license under certain patents, and a non-exclusive license to certain know-how, in each case controlled by Onyx and relating to the Company’s immunoproteasome program. The Company may be required to make future payments of up to $172.5 million upon achievement of certain development and commercial milestones for KZR-616, as well as royalty payments in the mid to high single digits on future annual net sales, if any.